Nintedanib plus docetaxel after progression on immune checkpoint inhibitor therapy: insights from VARGADO, a prospective study in patients with lung adenocarcinoma
Christian Grohé, Wolfgang Gleiber, Siegfried Haas, Christoph Losem, Harald Mueller-Huesmann, Mathias Schulze, Christian Franke, Nadezda Basara, Judith Atz, Rolf Kaiser, Christian Grohé, Wolfgang Gleiber, Siegfried Haas, Christoph Losem, Harald Mueller-Huesmann, Mathias Schulze, Christian Franke, Nadezda Basara, Judith Atz, Rolf Kaiser
Abstract
Aim: To assess outcomes in patients with advanced adenocarcinoma non-small-cell lung cancer who received nintedanib plus docetaxel after progression on prior chemotherapy followed by immune checkpoint inhibitor (ICI) therapy. Patients & methods: VARGADO is a prospective, noninterventional study. We describe initial data from a cohort of 22 patients who received nintedanib plus docetaxel after chemotherapy and ICI therapy. Results: Median progression-free survival with nintedanib plus docetaxel was 5.5 months (95% CI: 1.9-8.7 months). The objective response rate was 7/12 (58%) and the disease control rate was 10/12 (83%). Data for overall survival rate 12 months after the start of treatment (primary end point) are not yet mature and are not reported. Of 22 patients, 73% experienced drug-related adverse events; adverse events led to treatment discontinuation in 32% of patients. Conclusion: These data highlight the potential clinical benefit of nintedanib plus docetaxel in patients who failed prior ICI therapy. Trial registration number: NCT02392455.
Keywords: VARGADO; angio-immunogenic switch; docetaxel; nintedanib; non-small-cell lung cancer; tumor microenvironment.
Source: PubMed